Tarsus Pharmaceuticals' Xdemvy, the first approved treatment for Demodex blepharitis, generated $180M in 2024 sales, with significant growth potential in a large addressable market. Analysts ...

IRVINE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced financial results for the fourth quarter and full-year ended December 31, 2024 ...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a ...

(RTTNews) - Tarsus Pharmaceuticals, Inc (TARS) released Loss for fourth quarter that decreased from last year and beat the Street estimates. The company's earnings totaled -$23.113 million ...

Now, only three characters are left in the competition, with Dressed Crab, Pufferfish and Wolf set to battle it out for the crown. Dressed Crab has blown up on social media, as the stylish ...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a ...

LDWF said if you think you have caught a Chinese mitten crab, let them know by reporting any sightings to their Aquatic Invasive Species Hotline at (225) 765-3977.

After hours: March 14 at 7:44:48 PM EDT Loading Chart for TARS ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.